Log in

ProQR Therapeutics Stock Price, News & Analysis (NASDAQ:PRQR)

$6.22
-0.08 (-1.27 %)
(As of 10/16/2019 06:30 AM ET)
Today's Range
$6.19
Now: $6.22
$6.71
50-Day Range
$5.80
MA: $6.74
$7.74
52-Week Range
$5.62
Now: $6.22
$24.00
Volume105,347 shs
Average Volume170,369 shs
Market Capitalization$241.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.15
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.83 per share

Profitability

Net Income$-43,570,000.00

Miscellaneous

Employees118
Market Cap$241.77 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.


ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) issued its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.11. View ProQR Therapeutics' Earnings History.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for ProQR Therapeutics.

What price target have analysts set for PRQR?

5 Wall Street analysts have issued 12-month price objectives for ProQR Therapeutics' shares. Their predictions range from $20.00 to $40.00. On average, they expect ProQR Therapeutics' stock price to reach $30.40 in the next year. This suggests a possible upside of 388.7% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.

What is the consensus analysts' recommendation for ProQR Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.

What are Wall Street analysts saying about ProQR Therapeutics stock?

Here are some recent quotes from research analysts about ProQR Therapeutics stock:
  • 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (8/14/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $20.7/share, as a 25x multiple of taxed and diluted $10.07 discounted back to FY19 at 32% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $18.8/ share (discounted cash flow analysis using a 22% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (2/28/2019)
  • 3. Cantor Fitzgerald analysts commented, "We think the company’s RNA-based platform for inherited eye diseases has significant potential. The company established the initial proof of concept for their approach this past September. QR-110, the company’s lead ophthalmology asset, led to meaningful vision improvements in patients with a specific type of inherited blindness called LCA10. The company is applying this approach to many additional genetic eye diseases. For instance, we model peak sales potential of $1.1B for QR-411 which are being studied in other inherited forms of blindness." (12/13/2018)

Has ProQR Therapeutics been receiving favorable news coverage?

Media coverage about PRQR stock has been trending very negative recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ProQR Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the next few days. View News Stories for ProQR Therapeutics.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,430,000 shares, a decrease of 6.5% from the August 30th total of 1,530,000 shares. Based on an average daily volume of 163,600 shares, the short-interest ratio is presently 8.7 days. Currently, 4.8% of the shares of the company are short sold. View ProQR Therapeutics' Current Options Chain.

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Uniqure (QURE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM) and Viking Therapeutics (VKTX).

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the folowing people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)
  • Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)
  • Ms. Lisa A. Hayes, VP of Investor Relations & Corp. Communications
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Mr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55)

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $6.22.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $241.77 million. The biopharmaceutical company earns $-43,570,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe.View Additional Information About ProQR Therapeutics.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is http://www.proqr.com/.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  471
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: What is a price target?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel